Clinical Trials & Published Reports
Since founding Rational Therapeutics almost 20 years ago, Dr. Nagourney, his team and colleagues have published a number of papers supporting the use of the Ex-Vivo Analysis of Programmed Cell Death, as well as effectiveness of new drugs and combinations. We have selected a few of our most prominent papers since 2000 to make available for download on this site. If you would like copies of any papers not listed below, please contact our office at 562.989.6455.
Robert A. Nagourney, Jonathan B. Blitzer, Robert L. Shuman, Thomas J. Asciuto, Eknath A. Deo, Marylyn Paulsen, Robert L. Newcomb, Steve S. Evan. Anticancer Research, Vol. 32, No. 10: 4453-60, October 2012
Functional profiling using ex-vivo analysis of programmed cell death (EVA/PCD®) was shown, in a Phase II clinical trial conducted by a team of investigators at Rational Therapeutics and the MemorialCare Todd Cancer Institute, to have doubled the response rate of patients who received first-line chemotherapy based on their individual EVA-PCD assay. Using this methodology to select treatment also improved the time-to-progression and survival in patients with advanced lung cancer.
Foster C. Gonsalves, Karen Klein, Brittany B. Carson, Shauna Katz, Laura A. Ekas, Steve Evans, Robert Nagourney, Timothy Cardoza, Anthony M. C. Brown, and Ramanju DasGupta. PNAS Vol 108; No15:5954-5963 Apr 2011.
The WNT pathway was originally described in fruit flies as a determinate of wing shape. It was subsequently shown to be an important factor in human stem cell differentiation. Recognizing the importance of this pathway, the investigators at NYU and Cornell used a technology known as small interfering RNA (SIRNA) to shut down the WNT signal. They then screened 14,000 know chemicals for activity that mimicked the SIRNA effect. Three compounds were identified.
Cheryl A. Brewer, John A. Blessing, Robert A. Nagourney, D. Scott McMeekin, Shashikant Lele, and Susan L. Zweizig. Gynecol Oncol. 100(2):385-8, Feb 2006
This study suggests modest activity for the gemcitabine plus cisplatin doublet in previously treated squamous call carcinoma of the cervix. The objective response of 22 percent is comparable to that of other active agents and combinations tested in this setting. Toxicities were primarily hematologic and generally manageable with dose reductions.
By Robert A. Nagourney, John S. Link, Jonathan B. Blitzer, Cynthia Forsthoff, and Steven S. Evans. J Clin Oncol. Vol 18, Issue 11, 2000:2245-2249
Cisplatin plus gemcitabine is active and tolerable for patients with relapsed breast cancer. Responses observed in previously treated patients, including high-dose/stem-cell failures, indicate activity in otherwise drug-refractory patients.
Robert A. Nagourney, MD; Cheryl A. Brewer, MD; Stephen Radecki, PhD; Wesley A. Kidder; Barbara L. Sommers, RN; Steven S. Evans, MA; David R. Minor, MD; and Philip J. DiSaia, MD. Gynecol Oncol. 88, 35-39 (2003)
Cisplatin plus gemcitabine is active for patients with relapsed ovarian cancer. Toxicities, primarily hematologic, are manageable with dose modifications. Responses observed in heavily pretreated and platin-resistant patients indicate activity in drug-refractory patients. The results of the Ex Vivo Analyses correlate with clinical outcomes.
Robert A. Nagourney, MD. Current Treatment Options in Oncology, Vol 7, issue 2, March 2006.
Robert A. Nagourney, Marshall Flam, John Link, Steven Hager, Jonathan Blitzer, William Lyons, Barbara L. Sommers, and Steven Evans. Clin Breast Cancer, Oct 2008
The repeating doublet of split-dose carboplatin plus gemcitabine reveals activity comparable to that of cisplatin plus gemcitabine, is well tolerated and warrents evaluation in patients with recurrent breast cancer.
Robert A. Nagourney, MD. Clin Breast Ca Vol 5; No 2:123-124, 2000. Nagourney RA: Letter to the Editor. Gynecol Oncol. 76(1):143, 2000
As the platinum agents gain popularity in the management of breast cancer, this important class of drugs has the potential to improve outcome for one of the most common human malignancies.
Cheryl A. Brewer, John A. Blessing, Robert A. Nagourney, Mark Morgan, Parviz Hanjani. Gynecol Oncol. 2006 Apr 24
Cisplatin plus gemcitabine, in the doses and schedule employed, has modest activity in this patient population.